{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:42:40Z","timestamp":1793997760491,"version":"4.8.0"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.atherosclerosis.2022.04.015","type":"journal-article","created":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T20:48:27Z","timestamp":1653079707000},"page":"7-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":124,"special_numbering":"C","title":["Lipoprotein(a) and cardiovascular and valvular diseases: A genetic epidemiological perspective"],"prefix":"10.1016","volume":"349","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2240-8456","authenticated-orcid":false,"given":"Benoit J.","family":"Arsenault","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia R.","family":"Kamstrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib1","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1699-0463.1963.tb01808.x","article-title":"A New serum type system IN MAN--THE LP system","volume":"59","author":"Berg","year":"1963","journal-title":"Acta Pathol. Microbiol. Scand."},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib2","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1194\/jlr.R067314","article-title":"Structure, function, and genetics of lipoprotein (a)","volume":"57","author":"Schmidt","year":"2016","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib3","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1001\/jama.1993.03510180065035","article-title":"A prospective study of lipoprotein(a) and the risk of myocardial infarction","volume":"270","author":"Ridker","year":"1993","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0021-9150(94)90078-7","article-title":"Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study","volume":"106","author":"Alfthan","year":"1994","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib5","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/clinchem\/hvaa247","article-title":"Lipoprotein(a) and cardiovascular disease","volume":"67","author":"Kamstrup","year":"2021","journal-title":"Clin. Chem."},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib6","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1161\/ATV.0000000000000147","volume":"42","author":"Reyes-Soffer","year":"2022","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.atherosclerosis.2022.04.003","article-title":"Lipoprotein(a) beyond the kringle IV repeat polymorphism: the complexity of genetic variation in the LPA gene","volume":"349","author":"Coassin","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib8","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1016\/j.jacc.2016.10.033","article-title":"CHARGE\u2013Heart failure consortium, CARDIoGRAM exome consortium, phenotypic characterization of genetically lowered human lipoprotein(a) levels","volume":"68","author":"Emdin","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib9","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jacc.2017.11.014","article-title":"NHLBI working group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis","volume":"71","author":"Tsimikas","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib10","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1096\/fasebj.12.6.433","article-title":"Lipoprotein(a) and lipoprotein profile in healthy centenarians: a reappraisal of vascular risk factors","volume":"12","author":"Baggio","year":"1998","journal-title":"Faseb. J."},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib11","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.atherosclerosis.2022.04.008","article-title":"Lipoprotein(a) measurement issues: are we making a mountain out of a molehill?","volume":"349","author":"Kronenberg","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib12","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1038\/s41467-019-11558-2","article-title":"A meta-analysis of genome-wide association studies identifies multiple longevity genes","volume":"10","author":"Deelen","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib13","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.39856","article-title":"Genomics of 1 million parent lifespans implicates novel pathways and common diseases and distinguishes survival chances","volume":"8","author":"Timmers","year":"2019","journal-title":"Elife"},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s42003-019-0290-0","article-title":"Identification of 12 genetic loci associated with human healthspan","volume":"2","author":"Zenin","year":"2019","journal-title":"Commun Biol"},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib15","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1093\/eurheartj\/ehy902","article-title":"High lipoprotein(a) and high risk of mortality","volume":"40","author":"Langsted","year":"2019","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib16","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.0129","article-title":"Association of long-term exposure to elevated lipoprotein(a) levels with parental life span, chronic disease-free survival, and mortality risk: a mendelian randomization analysis","volume":"3","author":"Arsenault","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib17","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib18","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/j.jacc.2009.10.080","article-title":"Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants","volume":"55","author":"Erqou","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib19","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"PROCARDIS Consortium, Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib20","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/ije\/dyh132","article-title":"Mendelian randomization: prospects, potentials, and limitations","volume":"33","author":"Smith","year":"2004","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib21","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.atherosclerosis.2022.04.013","article-title":"Mendelian randomization - principles and its usage in lipoprotein(a) research","volume":"349","author":"Lamina","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib22","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1161\/01.ATV.12.10.1214","article-title":"Apo(a) isoforms predict risk for coronary heart disease. A study in six populations","volume":"12","author":"Sandholzer","year":"1992","journal-title":"Arterioscler. Thromb."},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib23","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1161\/ATVBAHA.119.312951","article-title":"Lipoprotein(a)-Lowering by 50 mg\/dL (105 nmol\/L) may Be needed to reduce cardiovascular disease 20% in secondary prevention: a population-based study","volume":"40","author":"Madsen","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib24","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1161\/CIRCULATIONAHA.117.031356","article-title":"LPA variants are associated with residual cardiovascular risk in patients receiving statins","volume":"138","author":"Wei","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib25","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","article-title":"Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials","volume":"392","author":"Willeit","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib26","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1161\/CIRCULATIONAHA.116.020838","article-title":"Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans","volume":"134","author":"van der Valk","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib27","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jacl.2018.02.007","article-title":"Elevated lipoprotein(a) levels are associated with coronary artery calcium scores in asymptomatic individuals with a family history of premature atherosclerotic cardiovascular disease","volume":"12","author":"Verweij","year":"2018","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib28","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jcct.2020.06.002","article-title":"Lipoprotein (a) and risk for calcification of the coronary arteries, mitral valve, and thoracic aorta: the Multi-Ethnic Study of Atherosclerosis","volume":"15","author":"Garg","year":"2021","journal-title":"J. Cardiovasc. Comput. Tomogr."},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib29","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ijcard.2016.07.219","article-title":"Increased risk of coronary artery calcification progression in subjects with high baseline Lp(a) levels: the Kangbuk Samsung Health Study","volume":"222","author":"Cho","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib30","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.atherosclerosis.2017.06.026","article-title":"Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: insights from SATURN","volume":"263","author":"Puri","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib31","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2019.10.019","article-title":"Lipoprotein(a) concentration and risks of cardiovascular disease and diabetes","volume":"74","author":"Gudbjartsson","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib32","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1161\/ATVBAHA.112.248765","article-title":"Genetic evidence that lipoprotein(a) associates with atherosclerotic stenosis rather than venous thrombosis","volume":"32","author":"Kamstrup","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib33","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1093\/eurheartj\/ehx174","article-title":"A novel but frequent variant in LPA KIV-2 is associated with a pronounced Lp(a) and cardiovascular risk reduction","volume":"38","author":"Coassin","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib34","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.jacc.2021.05.037","article-title":"GCKD investigators, frequent LPA KIV-2 variants lower lipoprotein(a) concentrations and protect against coronary artery disease","volume":"78","author":"Schachtl-Riess","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib35","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S2213-8587(17)30088-8","article-title":"Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a mendelian randomisation analysis","volume":"5","author":"Saleheen","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib36","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.jacc.2021.07.016","article-title":"High-sensitivity C-reactive protein modifies the cardiovascular risk of lipoprotein(a): multi-ethnic study of atherosclerosis","volume":"78","author":"Zhang","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib37","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1001\/jamacardio.2020.2413","article-title":"Effect of C-reactive protein on lipoprotein(a)-associated cardiovascular risk in optimally treated patients with high-risk vascular disease: a prespecified secondary analysis of the ACCELERATE trial","volume":"5","author":"Puri","year":"2020","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154706","article-title":"Lipoprotein (a) and coronary artery calcification: prospective study assessing interactions with other risk factors","volume":"116","author":"Ong","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib39","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1093\/eurheartj\/ehy334","article-title":"Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting","volume":"39","author":"Verbeek","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib40","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jacc.2018.04.060","article-title":"Lipoprotein(a) and cardiovascular risk prediction among women","volume":"72","author":"Cook","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib41","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.120.003271","article-title":"Sex-specific associations of genetically predicted circulating lp(a) (Lipoprotein(a)) and hepatic LPA gene expression levels with cardiovascular outcomes: mendelian randomization and observational analyses","volume":"14","author":"Guertin","year":"2021","journal-title":"Circ. Genom. Precis Med."},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib42","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.atherosclerosis.2016.11.010","article-title":"Ideal cardiovascular health influences cardiovascular disease risk associated with high lipoprotein(a) levels and genotype: the EPIC-Norfolk prospective population study","volume":"256","author":"Perrot","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib43","doi-asserted-by":"crossref","first-page":"15660","DOI":"10.1038\/s41598-021-95141-0","article-title":"Lipoprotein (a) level as a risk factor for stroke and its subtype: a systematic review and meta-analysis","volume":"11","author":"Kumar","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib44","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1161\/01.ATV.16.12.1568","article-title":"Lipoprotein(a) in stored plasma samples and the ravages of time. Why epidemiological studies might fail","volume":"16","author":"Kronenberg","year":"1996","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib45","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1194\/jlr.R061648","article-title":"Lipoprotein (a) measurements for clinical application","volume":"57","author":"Marcovina","year":"2016","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib46","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1093\/clinchem\/46.12.1956","article-title":"Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a)","volume":"46","author":"Marcovina","year":"2000","journal-title":"Clin. Chem."},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib47","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1093\/eurheartj\/ehab081","article-title":"Lipoprotein(a) is associated with large artery atherosclerosis stroke aetiology and stroke recurrence among patients below the age of 60 years: results from the BIOSIGNAL study","volume":"42","author":"Arnold","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib48","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1161\/CIRCGENETICS.110.958371","article-title":"Heart Protection Study Collaborative Group, Lipoprotein(a) genetic variants associated with coronary and peripheral vascular disease but not with stroke risk in the Heart Protection Study","volume":"4","author":"Hopewell","year":"2011","journal-title":"Circ. Cardiovasc. Genet."},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib49","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jacc.2019.03.524","article-title":"Elevated lipoprotein(a) and risk of ischemic stroke","volume":"74","author":"Langsted","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib50","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1038\/s41591-019-0492-5","article-title":"Genome-wide association study of peripheral artery disease in the Million Veteran Program","volume":"25","author":"Klarin","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib51","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jvs.2015.08.114","article-title":"Sex and ethnic differences in the associations between lipoprotein(a) and peripheral arterial disease in the Multi-Ethnic Study of Atherosclerosis","volume":"63","author":"Forbang","year":"2016","journal-title":"J. Vasc. Surg."},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib52","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.amjcard.2010.01.370","article-title":"Lipoprotein(a), inflammation, and peripheral arterial disease in a community-based sample of older men and women (the InCHIANTI study)","volume":"105","author":"Volpato","year":"2010","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib53","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1161\/ATVBAHA.112.255521","article-title":"Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study","volume":"32","author":"Gurdasani","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib54","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.015355","article-title":"Association of serum lipoprotein (a) with the requirement for a peripheral artery operation and the incidence of major adverse cardiovascular events in people with peripheral artery disease","volume":"9","author":"Golledge","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib55","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/cvr\/cvu107","article-title":"Lipoprotein (a) concentrations, apolipoprotein (a) phenotypes, and peripheral arterial disease in three independent cohorts","volume":"103","author":"Laschkolnig","year":"2014","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib56","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1161\/CIRCULATIONAHA.105.608679","article-title":"Risk factors for progression of peripheral arterial disease in large and small vessels","volume":"113","author":"Aboyans","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib57","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S0735-1097(96)00563-3","article-title":"Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study","volume":"29","author":"Stewart","year":"1997","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib58","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S0195-668X(02)00385-8","article-title":"Lipoprotein(a), Chlamydia pneumoniae, leptin and tissue plasminogen activator as risk markers for valvular aortic stenosis","volume":"24","author":"Glader","year":"2003","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib59","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1109034","article-title":"CHARGE Extracoronary Calcium Working Group, Genetic associations with valvular calcification and aortic stenosis","volume":"368","author":"Thanassoulis","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib60","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population","volume":"63","author":"Kamstrup","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib61","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCGENETICS.113.000400","article-title":"Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective Mendelian randomization study and replication in a case-control cohort","volume":"7","author":"Arsenault","year":"2014","journal-title":"Circ. Cardiovasc. Genet."},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib62","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.jacc.2015.07.020","article-title":"Oxidized phospholipids, lipoprotein(a), and progression of calcific aortic valve stenosis","volume":"66","author":"Capoulade","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib63","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.jacc.2019.01.070","article-title":"Lipoprotein(a) and oxidized phospholipids promote valve calcification in patients with aortic stenosis","volume":"73","author":"Zheng","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib64","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.cjco.2019.03.004","article-title":"Lipoprotein(a), oxidized phospholipids, and aortic valve microcalcification assessed by 18F-sodium fluoride Positron emission tomography and computed tomography","volume":"1","author":"Despr\u00e9s","year":"2019","journal-title":"CJC Open"},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib65","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1001\/jamacardio.2019.1581","article-title":"Genetic variation in LPA, calcific aortic valve stenosis in patients undergoing cardiac surgery, and familial risk of aortic valve microcalcification","volume":"4","author":"Perrot","year":"2019","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib66","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jchf.2015.08.006","article-title":"Elevated lipoprotein(a) levels, LPA risk genotypes, and increased risk of heart failure in the general population","volume":"4","author":"Kamstrup","year":"2016","journal-title":"JACC Heart Fail."},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib67","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.atherosclerosis.2017.05.014","article-title":"The association of lipoprotein(a) with incident heart failure hospitalization: atherosclerosis Risk in Communities study","volume":"262","author":"Agarwala","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib68","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1161\/ATVBAHA.118.311220","article-title":"Lp(a) [Lipoprotein(a)]-Related risk of heart failure is evident in whites but not in other racial\/ethnic groups","volume":"38","author":"Steffen","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib69","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1373\/clinchem.2010.146779","article-title":"Lipoprotein(a) and risk of type 2 diabetes","volume":"56","author":"Mora","year":"2010","journal-title":"Clin. Chem."},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib70","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S2213-8587(13)70064-0","article-title":"Lipoprotein(a) concentrations, isoform size, and risk of type 2 diabetes: a Mendelian randomisation study","volume":"1","author":"Kamstrup","year":"2013","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib71","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.atherosclerosis.2022.04.016","article-title":"Lipoprotein(a) and diabetes mellitus","volume":"349","author":"Lamina","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib72","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.atherosclerosis.2022.04.009","article-title":"Beyond fibrinolysis: the confounding role of Lp(a) in thrombosis","volume":"349","author":"Boffa","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib73","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0031954","article-title":"JMS Cohort Study Group, Low lipoprotein(a) concentration is associated with cancer and all-cause deaths: a population-based cohort study (the JMS cohort study)","volume":"7","author":"Sawabe","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib74","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/CEJ.0b013e328359cba7","article-title":"Lipoprotein(a) plasma levels and the risk of cancer: the PRIME study","volume":"22","author":"Marrer","year":"2013","journal-title":"Eur. J. Cancer Prev."},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib75","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003859","article-title":"The relationship between lipoprotein A and other lipids with prostate cancer risk: a multivariable Mendelian randomisation study","volume":"19","author":"Ioannidou","year":"2022","journal-title":"PLoS Med."},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib76","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/eurheartj\/ehaa1085","article-title":"Low lipoprotein(a) levels and risk of disease in a large, contemporary, general population study","volume":"42","author":"Langsted","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2022.04.015_bib77","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.atherosclerosis.2022.04.020","article-title":"Existing and evolving strategies to lower lipoprotein(a)","volume":"349","author":"Schwartz","year":"2022","journal-title":"Atherosclerosis"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915022001940?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915022001940?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:50:50Z","timestamp":1758156650000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915022001940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":77,"alternative-id":["S0021915022001940"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.04.015","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipoprotein(a) and cardiovascular and valvular diseases: A genetic epidemiological perspective","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.04.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}